Symbols / EOLS Stock $6.56 -0.15% Evolus, Inc.

Healthcare • Drug Manufacturers - Specialty & Generic • United States • NGM
EOLS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO Mr. David Moatazedi
Exch · Country NGM · United States
Market Cap 432.01M
Enterprise Value 547.12M
Income -43.42M
Sales 301.79M
FCF (ttm) -23.23M
Book/sh -0.44
Cash/sh 0.76
Employees 350
Insider 10d —
IPO Feb 08, 2018
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 24.60
PEG —
P/S 1.43
P/B -15.01
P/C —
EV/EBITDA -23.63
EV/Sales 1.81
Quick Ratio 1.50
Current Ratio 2.04
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -0.66
EPS next Y 0.27
EPS Growth —
Revenue Growth 6.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-04
ROA -9.06%
ROE —
ROIC —
Gross Margin 66.05%
Oper. Margin -9.38%
Profit Margin -14.39%
Shs Outstand 65.85M
Shs Float 50.04M
Insider Own 14.68%
Instit Own 70.05%
Short Float 9.49%
Short Ratio 6.52
Short Interest 6.17M
52W High 10.62
vs 52W High -38.23%
52W Low 3.86
vs 52W Low 69.95%
Beta 1.29
Impl. Vol. 29.41%
Rel Volume 0.71
Avg Volume 1.13M
Volume 799.08K
Target (mean) $14.67
Tgt Median $14.00
Tgt Low $10.00
Tgt High $20.00
# Analysts 6
Recom Strong_buy
Prev Close $6.57
Price $6.56
Change -0.15%
About

Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$14.67
Mean price target
2. Current target
$6.56
Latest analyst target
3. DCF / Fair value
$-6.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.56
Low
$10.00
High
$20.00
Mean
$14.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-04 reit BTIG Buy → Buy $13
2026-02-03 main HC Wainwright & Co. Buy → Buy $13
2026-01-22 main BTIG Buy → Buy $13
2026-01-13 main Stifel Buy → Buy $17
2026-01-09 reit HC Wainwright & Co. Buy → Buy $20
2025-12-24 reit Needham Hold → Hold —
2025-12-02 main Mizuho Outperform → Outperform $19
2025-09-08 reit BTIG Buy → Buy $18
2025-08-06 main BTIG Buy → Buy $18
2025-08-06 down Needham Buy → Hold $22
2025-08-06 main HC Wainwright & Co. Buy → Buy $20
2025-05-08 reit Needham Buy → Buy $22
2025-04-17 init BTIG — → Buy $21
2025-04-10 reit HC Wainwright & Co. Buy → Buy $27
2025-04-09 reit Needham Buy → Buy $22
2025-03-05 main Barclays Overweight → Overweight $25
2025-03-05 reit HC Wainwright & Co. Buy → Buy $27
2025-03-05 reit Needham Buy → Buy $22
2025-02-14 reit HC Wainwright & Co. Buy → Buy $27
2025-01-27 main Barclays Overweight → Overweight $22
News
RSS: Latest EOLS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-20 AVELAR RUI L. Officer — 3,119 $4.75 $14,815
2026-03-20 MOATAZEDI DAVID Chief Executive Officer — 13,669 $4.75 $64,929
2026-03-17 AVELAR RUI L. Officer — 29,996 $4.89 $146,629
2026-03-17 MOATAZEDI DAVID Chief Executive Officer — 116,720 $4.89 $570,562
2026-03-16 AVELAR RUI L. Officer — 8,804 — —
2026-03-16 MOATAZEDI DAVID Chief Executive Officer — 67,489 — —
2026-02-17 GILL DAVID N. Director — 45,559 $0.00 $0
2026-02-17 WHITE ALBERT G III Director — 45,559 $0.00 $0
2026-02-17 AVELAR RUI L. Officer — 94,913 $0.00 $0
2026-02-17 PARSCHAUER KARAH HERDMAN Director — 45,559 $0.00 $0
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
297.18
+11.61%
266.27
+31.76%
202.09
+35.98%
148.62
Operating Revenue
297.18
+11.61%
266.27
+31.76%
202.09
+35.98%
148.62
Cost Of Revenue
100.07
+19.17%
83.97
+30.16%
64.51
+9.64%
58.84
Reconciled Cost Of Revenue
95.67
+19.15%
80.29
+32.00%
60.83
+10.37%
55.11
Gross Profit
197.11
+8.12%
182.30
+32.52%
137.57
+53.24%
89.77
Operating Expense
234.71
+12.01%
209.54
+14.79%
182.55
+22.23%
149.35
Research And Development
9.58
+4.40%
9.17
-40.54%
15.43
+128.79%
6.74
Selling General And Administration
220.79
+11.49%
198.03
+20.06%
164.94
+16.29%
141.84
Total Expenses
334.78
+14.06%
293.51
+18.80%
247.06
+18.67%
208.19
Operating Income
-37.60
-38.06%
-27.23
+39.45%
-44.98
+24.51%
-59.58
Total Operating Income As Reported
-32.66
+5.08%
-34.41
+30.11%
-49.23
+24.64%
-65.33
EBITDA
-22.53
+9.90%
-25.00
+40.20%
-41.81
+31.15%
-60.72
Normalized EBITDA
-21.08
+15.67%
-25.00
+40.20%
-41.81
+31.15%
-60.72
Reconciled Depreciation
8.74
+45.23%
6.02
+2.61%
5.87
+30.46%
4.50
EBIT
-31.27
-0.80%
-31.02
+34.94%
-47.68
+26.90%
-65.22
Total Unusual Items
-1.44
0.00
0.00
0.00
Total Unusual Items Excluding Goodwill
-1.44
0.00
0.00
0.00
Special Income Charges
-1.44
0.00
0.00
0.00
Other Special Charges
—
—
—
2.00
Restructuring And Mergern Acquisition
1.44
0.00
0.00
—
Net Income
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Pretax Income
-50.96
-2.43%
-49.76
+19.11%
-61.51
+17.23%
-74.32
Net Non Operating Interest Income Expense
-17.76
-14.81%
-15.47
-19.27%
-12.97
-44.49%
-8.98
Interest Expense Non Operating
19.69
+5.12%
18.73
+35.45%
13.83
+52.05%
9.10
Net Interest Income
-17.76
-14.81%
-15.47
-19.27%
-12.97
-44.49%
-8.98
Interest Expense
19.69
+5.12%
18.73
+35.45%
13.83
+52.05%
9.10
Interest Income Non Operating
1.93
-40.82%
3.26
+279.42%
0.86
+622.69%
0.12
Interest Income
1.93
-40.82%
3.26
+279.42%
0.86
+622.69%
0.12
Other Income Expense
4.40
+162.41%
-7.05
-97.95%
-3.56
+38.22%
-5.76
Other Non Operating Income Expenses
5.84
+182.88%
-7.05
-97.95%
-3.56
+38.22%
-5.76
Tax Provision
0.68
+1.96%
0.66
+277.27%
0.18
+85.26%
0.10
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.30
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Net Income From Continuing Operation Net Minority Interest
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Net Income From Continuing And Discontinued Operation
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Net Income Continuous Operations
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Normalized Income
-50.50
-0.16%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Net Income Common Stockholders
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Diluted EPS
-0.80
+1.23%
-0.81
+25.00%
-1.08
+18.80%
-1.33
Basic EPS
-0.80
+1.23%
-0.81
+25.00%
-1.08
+18.80%
-1.33
Basic Average Shares
64.47
+3.57%
62.25
+9.36%
56.92
+1.52%
56.06
Diluted Average Shares
64.47
+3.57%
62.25
+9.36%
56.92
+1.52%
56.06
Diluted NI Availto Com Stockholders
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Depreciation Amortization Depletion Income Statement
4.34
+85.53%
2.34
+7.53%
2.18
+183.96%
0.77
Depreciation And Amortization In Income Statement
4.34
+85.53%
2.34
+7.53%
2.18
+183.96%
0.77
Line Item Trend 2023-12-31
Total Assets
189.00
Current Assets
112.42
Cash Cash Equivalents And Short Term Investments
62.84
Cash And Cash Equivalents
62.84
Other Short Term Investments
—
Receivables
30.53
Accounts Receivable
30.53
Gross Accounts Receivable
32.02
Allowance For Doubtful Accounts Receivable
-1.49
Inventory
11.00
Prepaid Assets
5.70
Other Current Assets
2.36
Total Non Current Assets
76.58
Net PPE
7.85
Gross PPE
10.25
Accumulated Depreciation
-2.40
Properties
0.00
Machinery Furniture Equipment
2.19
Other Properties
5.84
Leases
2.21
Goodwill And Other Intangible Assets
68.32
Goodwill
21.21
Other Intangible Assets
47.11
Other Non Current Assets
0.41
Total Liabilities Net Minority Interest
209.69
Current Liabilities
48.29
Payables And Accrued Expenses
35.88
Payables
13.10
Accounts Payable
4.27
Current Accrued Expenses
22.78
Pensionand Other Post Retirement Benefit Plans Current
—
Current Debt And Capital Lease Obligation
1.38
Current Capital Lease Obligation
1.38
Current Deferred Liabilities
11.03
Current Deferred Revenue
11.03
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
161.40
Long Term Debt And Capital Lease Obligation
125.17
Long Term Debt
120.36
Long Term Capital Lease Obligation
4.81
Tradeand Other Payables Non Current
0.00
Non Current Deferred Liabilities
0.03
Non Current Deferred Taxes Liabilities
0.03
Stockholders Equity
-20.69
Common Stock Equity
-20.69
Capital Stock
0.00
Common Stock
0.00
Preferred Stock
0.00
Share Issued
57.82
Ordinary Shares Number
57.82
Treasury Shares Number
0.00
Additional Paid In Capital
538.72
Retained Earnings
-558.98
Gains Losses Not Affecting Retained Earnings
-0.43
Other Equity Adjustments
-0.43
Total Equity Gross Minority Interest
-20.69
Total Capitalization
99.67
Working Capital
64.13
Invested Capital
99.67
Total Debt
126.55
Net Debt
57.52
Capital Lease Obligations
6.19
Net Tangible Assets
-89.01
Tangible Book Value
-89.01
Current Notes Payable
—
Dueto Related Parties Current
8.83
Dueto Related Parties Non Current
36.20
Non Current Accrued Expenses
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-42.27
-134.82%
-18.00
+47.07%
-34.01
+59.95%
-84.91
Cash Flow From Continuing Operating Activities
-42.27
-134.82%
-18.00
+47.07%
-34.01
+59.95%
-84.91
Net Income From Continuing Operations
-51.64
-2.42%
-50.42
+18.26%
-61.69
+17.10%
-74.41
Depreciation Amortization Depletion
8.74
+45.23%
6.02
+2.61%
5.87
+30.46%
4.50
Depreciation
8.74
+45.23%
6.02
+2.61%
5.87
+30.46%
4.50
Depreciation And Amortization
8.74
+45.23%
6.02
+2.61%
5.87
+30.46%
4.50
Other Non Cash Items
-4.12
-149.35%
8.36
-14.72%
9.80
+43.28%
6.84
Stock Based Compensation
20.70
-6.99%
22.25
+35.22%
16.46
+51.92%
10.83
Provisionand Write Offof Assets
6.51
+166.03%
2.45
+70.07%
1.44
-9.89%
1.60
Deferred Tax
0.02
+200.00%
-0.02
-520.00%
0.01
+127.78%
-0.02
Deferred Income Tax
0.02
+200.00%
-0.02
-520.00%
0.01
+127.78%
-0.02
Operating Gains Losses
—
—
—
—
Change In Working Capital
-22.48
-238.49%
-6.64
-12.64%
-5.89
+82.79%
-34.25
Change In Receivables
-11.51
+41.29%
-19.60
-105.88%
-9.52
-1.41%
-9.39
Changes In Account Receivables
-11.51
+41.29%
-19.60
-105.88%
-9.52
-1.41%
-9.39
Change In Inventory
-11.12
-442.07%
3.25
-22.44%
4.19
+139.23%
-10.69
Change In Prepaid Assets
-0.35
-115.10%
2.35
+230.76%
-1.80
-252.37%
1.18
Change In Payables And Accrued Expense
3.74
-49.26%
7.37
+145.47%
3.00
+115.61%
-19.23
Change In Accrued Expense
-6.36
-191.20%
6.98
+73.63%
4.02
+119.90%
-20.20
Change In Payable
10.10
+2483.89%
0.39
+138.45%
-1.02
-205.06%
0.97
Change In Account Payable
10.10
+2483.89%
0.39
+138.45%
-1.02
-205.06%
0.97
Change In Other Current Assets
-2.47
-449.72%
0.71
+181.71%
-0.86
-117.80%
4.85
Change In Other Current Liabilities
-0.76
-5.87%
-0.72
+21.06%
-0.91
+7.16%
-0.98
Investing Cash Flow
-8.45
-75.24%
-4.82
-196.44%
-1.63
+44.64%
-2.94
Cash Flow From Continuing Investing Activities
-8.45
-75.24%
-4.82
-196.44%
-1.63
+44.64%
-2.94
Net PPE Purchase And Sale
-3.44
-133.76%
-1.47
-211.21%
-0.47
+70.77%
-1.62
Purchase Of PPE
-3.44
-133.76%
-1.47
-211.21%
-0.47
+70.77%
-1.62
Capital Expenditure
-8.45
-75.24%
-4.82
-196.44%
-1.63
+44.64%
-2.94
Capital Expenditure Reported
-5.01
-49.54%
-3.35
-190.38%
-1.15
+12.64%
-1.32
Net Investment Purchase And Sale
—
—
—
0.00
Purchase Of Investment
—
—
—
—
Sale Of Investment
—
—
—
0.00
Financing Cash Flow
17.34
-63.43%
47.41
+6.21%
44.64
+1176.72%
-4.15
Cash Flow From Continuing Financing Activities
17.34
-63.43%
47.41
+6.21%
44.64
+1176.72%
-4.15
Net Issuance Payments Of Debt
24.98
0.00
-100.00%
50.00
0.00
Issuance Of Debt
25.00
0.00
-100.00%
50.00
0.00
Repayment Of Debt
-0.01
0.00
0.00
0.00
Long Term Debt Issuance
25.00
0.00
-100.00%
50.00
0.00
Long Term Debt Payments
-0.01
0.00
0.00
0.00
Net Long Term Debt Issuance
24.98
0.00
-100.00%
50.00
0.00
Net Common Stock Issuance
0.00
-100.00%
51.21
0.00
0.00
Proceeds From Stock Option Exercised
1.16
-76.16%
4.88
+2013.42%
0.23
-57.14%
0.54
Net Other Financing Charges
-8.81
-1.53%
-8.68
-55.26%
-5.59
-19.32%
-4.68
Changes In Cash
-33.38
-235.74%
24.59
+173.06%
9.01
+109.79%
-92.00
Effect Of Exchange Rate Changes
0.25
+153.14%
-0.48
-431.11%
-0.09
+73.29%
-0.34
Beginning Cash Position
86.95
+38.37%
62.84
+16.53%
53.92
-63.13%
146.26
End Cash Position
53.83
-38.10%
86.95
+38.37%
62.84
+16.53%
53.92
Free Cash Flow
-50.72
-122.23%
-22.82
+35.96%
-35.63
+59.44%
-87.85
Interest Paid Supplemental Data
14.79
-15.69%
17.55
+38.06%
12.71
+58.87%
8.00
Income Tax Paid Supplemental Data
1.22
+417.02%
0.23
+100.85%
0.12
+53.95%
0.08
Amortization Of Securities
—
—
—
0.00
Common Stock Issuance
0.00
-100.00%
51.21
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
51.21
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category